Follow
Andrew J. Armstrong
Title
Cited by
Cited by
Year
Increased survival with enzalutamide in prostate cancer after chemotherapy
HI Scher, K Fizazi, F Saad, ME Taplin, CN Sternberg, K Miller, R De Wit, ...
New England Journal of Medicine 367 (13), 1187-1197, 2012
52062012
Enzalutamide in metastatic prostate cancer before chemotherapy
TM Beer, AJ Armstrong, DE Rathkopf, Y Loriot, CN Sternberg, CS Higano, ...
New England Journal of Medicine 371 (5), 424-433, 2014
33542014
Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3
HI Scher, MJ Morris, WM Stadler, C Higano, E Basch, K Fizazi, ...
Journal of Clinical Oncology 34 (12), 1402-1418, 2016
13462016
Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology
JL Mohler, ES Antonarakis, AJ Armstrong, AV D’Amico, BJ Davis, T Dorff, ...
Journal of the National Comprehensive Cancer Network 17 (5), 479-505, 2019
12512019
ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer
AJ Armstrong, RZ Szmulewitz, DP Petrylak, J Holzbeierlein, A Villers, ...
Journal of Clinical Oncology 37 (32), 2974-2986, 2019
9262019
Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers
AJ Armstrong, MS Marengo, S Oltean, G Kemeny, RL Bitting, JD Turnbull, ...
Molecular cancer research 9 (8), 997-1007, 2011
7672011
Prostate cancer, version 1.2016
JL Mohler, AJ Armstrong, RR Bahnson, AV D'Amico, BJ Davis, ...
Journal of the National Comprehensive Cancer Network 14 (1), 19-30, 2016
7582016
Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity
B Shuch, A Amin, AJ Armstrong, JN Eble, V Ficarra, A Lopez-Beltran, ...
European urology 67 (1), 85-97, 2015
5402015
Enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study
TM Beer, AJ Armstrong, D Rathkopf, Y Loriot, CN Sternberg, CS Higano, ...
European urology 71 (2), 151-154, 2017
4662017
A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis
AJ Armstrong, ES Garrett-Mayer, YCO Yang, R De Wit, IF Tannock, ...
Clinical Cancer Research 13 (21), 6396-6403, 2007
4302007
Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer
S Halabi, WK Kelly, H Ma, H Zhou, NC Solomon, K Fizazi, CM Tangen, ...
Journal of clinical oncology 34 (14), 1652-1659, 2016
4262016
Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial
AJ Armstrong, S Halabi, T Eisen, S Broderick, WM Stadler, RJ Jones, ...
The Lancet Oncology 17 (3), 378-388, 2016
4182016
Prostate cancer, version 2.2014
JL Mohler, PW Kantoff, AJ Armstrong, RR Bahnson, M Cohen, ...
Journal of the National Comprehensive Cancer Network 12 (5), 686-718, 2014
3892014
Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide
KL Noonan, S North, RL Bitting, AJ Armstrong, SL Ellard, KN Chi
Annals of oncology 24 (7), 1802-1807, 2013
3832013
Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer
RL Bitting, AJ Armstrong
Endocrine-related cancer 20 (3), R83-R99, 2013
3762013
Enzalutamide versus bicalutamide in castration-resistant prostate cancer: the STRIVE trial
DF Penson, AJ Armstrong, R Concepcion, N Agarwal, C Olsson, L Karsh, ...
Journal of Clinical Oncology 34 (18), 2098-2106, 2016
3622016
NCCN guidelines insights: Prostate cancer, version 1.2021: Featured updates to the NCCN guidelines
E Schaeffer, S Srinivas, ES Antonarakis, AJ Armstrong, JE Bekelman, ...
Journal of the National Comprehensive Cancer Network 19 (2), 134-143, 2021
3552021
Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: the PROPHECY study
AJ Armstrong, S Halabi, J Luo, DM Nanus, P Giannakakou, ...
Journal of Clinical Oncology 37 (13), 1120-1129, 2019
3142019
Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer
AJ Armstrong, E Garrett-Mayer, YC Ou Yang, MA Carducci, I Tannock, ...
Journal of Clinical Oncology 25 (25), 3965-3970, 2007
3122007
Prostate cancer, version 3.2012 featured updates to the NCCN guidelines
JL Mohler, AJ Armstrong, RR Bahnson, B Boston, JE Busby, AV D’Amico, ...
Journal of the National Comprehensive Cancer Network 10 (9), 1081-1087, 2012
2832012
The system can't perform the operation now. Try again later.
Articles 1–20